Pfizer started construction of a $350 million Global Biotechnology Center in Hangzhou, which will manufacture affordable biosimilars for China and the world; China Resources Pharma, the country's second largest drugmaker, filed for a Hong Kong IPO that will raise at least $1 billion; Allergan, known for its Botox and ophthalmology products, has $20 billion to spend on deals and is looking for prospects in China; CoSci Med-Tech of Beijing led a $17 million Series A financing in US-based JDP Therapeutics; Neusoft Medical closed an investment from China Everbright for "significant strategic maneuvers;" Yabao Pharma formed a partnership with LFB Bio, a state-owned French company, to bring LFB's albumin product to China; Zhejiang Hisun Pharma acquired China rights for a novel flu treatment from Japan's Fujifilm; Jiangsu Egens Biotech in-licensed China rights to a hepatitis C diagnostic from BATM of Israeli; and BeyondSpring, a New York city biopharma, launched a China-US Phase III clinical trial of its lead cancer drug.
